Pharma News
This Week
May 7, 2025
Sandoz seeks to prevent Amgen's legal team from pursuing patent claims in ongoing intellectual property dispute - Lawyerly
Sandoz seeks to protect information revealed in preliminary discovery orders from Amgen's patent attorneys amid a dispute over generic versions of Amgen's bone disease drugs. Sandoz argues that if Amgen's attorneys access this material, they should be prohibited from pursuing future related patents.
May 6, 2025
Dermatology offshoot Dermavon submits IPO application, highlighting its vitiligo treatment as a key investment opportunity - Kr Asia
Dermavon Holdings, a subsidiary of China Medical System (CMS), is preparing for an IPO in Hong Kong, focusing on dermatology treatments, including the promising ruxolitinib cream for vitiligo. Despite not yet being approved in China, ruxolitinib has shown significant results globally. Dermavon aims to expand its portfolio while facing challenges in R&D and declining margins.
May 6, 2025
India's upcoming pharmaceutical transformation: Overcoming patent challenges to lead the $200 billion biosimilars industry.
India faces challenges in producing affordable biosimilars, crucial for treating chronic diseases, as many biologics go off-patent. Patent evergreening, particularly by companies like Roche and Merck, hinders progress. A report highlights India's potential to lead in biosimilars, with over 98 already approved. To capitalize, India must revise guidelines, curb evergreening, and boost domestic production for equitable healthcare.
May 5, 2025
Federal Circuit Maintains FDA Suspension in MSN-Novartis Patent Dispute - Bloomberg Law News
A Federal Circuit court has ordered a Delaware district court to maintain its pause on the FDA's final approval of MSN Laboratories Pvt. Ltd.’s generic version of Novartis AG’s heart-disease drug, Entresto. MSN is appealing rulings that prevent the early launch of its copy, preserving Novartis’ market exclusivity until July.
